Core Insights - Mamei Bio is a leading Chinese beauty company focused on anti-aging solutions, leveraging synthetic biology technology and over 20 years of experience in the skincare industry [4][5] - The company has developed a recombinant double collagen, a unique engineered protein that combines type I and type III collagen into a single molecule, enhancing its skincare products [4] - Mamei Bio has been recognized as the primary drafting unit for the national standard of "Recombinant Soluble Collagen" by the Ministry of Industry and Information Technology in 2023 [4] Company Overview - Mamei Bio operates two main brands: Mamei, focusing on anti-aging eye and facial care products, and Lianhuo, a cost-effective makeup brand [4] - The company has established a comprehensive value chain for core ingredients, developing over 80 proprietary components, with more than 30 achieving large-scale production [7] - Mamei Bio's production facilities are located in Guangzhou, China, and are equipped for high-density fermentation and purification processes for recombinant collagen production [7] Financial Performance - Mamei Bio's revenue for the years ending December 31 and the nine months ending September 30 are as follows: RMB 1.732 billion in 2022, RMB 2.226 billion in 2023, RMB 2.977 billion in 2024, and RMB 2.450 billion for the nine months of 2025 [8] - The company's profit for the same periods is reported as RMB 167 million in 2022, RMB 278 million in 2023, RMB 342 million in 2024, and RMB 247 million for the nine months of 2025 [9] - Gross profit figures are RMB 1.175 billion in 2022, RMB 1.560 billion in 2023, RMB 2.177 billion in 2024, and RMB 1.834 billion for the nine months of 2025 [10] Industry Overview - The Chinese beauty market is projected to grow from RMB 460.3 billion in 2019 to RMB 566.3 billion by 2024, with a compound annual growth rate (CAGR) of 4.2% [11] - The skincare segment is expected to expand from RMB 355.9 billion in 2019 to RMB 451.4 billion by 2024, with a CAGR of 4.9% [14] - The makeup segment is anticipated to grow from RMB 104.5 billion in 2019 to RMB 114.8 billion by 2024, with a CAGR of 1.9% [17]

Company Overview - Mamei Biotechnology is a leading Chinese beauty company focused on providing anti-aging solutions, leveraging synthetic biology technology and over 20 years of experience in the anti-aging skincare industry [4] - The company has successfully developed recombinant double collagen, a unique engineered collagen that combines type I and type III collagen into a single molecule, enhancing its skincare products [4] - Mamei Biotechnology has been recognized as a key drafting unit for the industry standard "Recombinant Soluble Collagen" by the Ministry of Industry and Information Technology in 2023 [4] Market Position - According to Frost & Sullivan, Mamei has ranked first in the Chinese domestic eye care brand market by retail sales from 2021 to 2024 [5] - The brand "Lianhuo" ranks third among domestic foundation brands and fifth among all foundation brands in China, with a compound annual growth rate (CAGR) of 77.5% from 2022 to 2024, the highest among the top five foundation brands [5] Product Development - Mamei has established a comprehensive value chain covering basic research to application for its core ingredients, having developed over 80 proprietary ingredients, with more than 30 achieving large-scale production [7] - The company operates two production bases in Guangzhou, which are capable of high-density fermentation and purification processes for recombinant collagen production [7] Financial Performance - The company reported revenues of RMB 1.73 billion, RMB 2.23 billion, RMB 2.97 billion, and RMB 2.45 billion for the years ending December 31, 2022, 2023, 2024, and the nine months ending September 30, 2025, respectively [9] - The annual profits for the same periods were RMB 167.43 million, RMB 277.59 million, RMB 342.36 million, and RMB 246.65 million [10] - Gross profits for the respective years were RMB 1.17 billion, RMB 1.56 billion, RMB 2.18 billion, and RMB 1.83 billion [11] Industry Overview - The Chinese beauty industry is projected to grow from RMB 460.3 billion in 2019 to RMB 566.3 billion by 2024, with a CAGR of 4.2% [12] - The skincare market is expected to expand from RMB 355.9 billion in 2019 to RMB 451.4 billion by 2024, with a CAGR of 4.9% [15] - The makeup market is anticipated to grow from RMB 104.5 billion in 2019 to RMB 114.8 billion by 2024, with a CAGR of 1.9% [18]

Group 1 - The core viewpoint of the article is that Guangdong Marubi Biotechnology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with Goldman Sachs and CITIC Securities as joint sponsors [1] - Marubi Biotechnology is a leading Chinese beauty company focused on providing anti-aging solutions, leveraging synthetic biology technology and over 20 years of experience in the anti-aging skincare industry [1] - The company emphasizes research and development, particularly in core technologies such as recombinant collagen, to innovate skincare products with anti-wrinkle, firming, and repairing effects [1] Group 2 - According to a report by Frost & Sullivan, Marubi Biotechnology is the third largest beauty company in China in the recombinant collagen skincare segment, based on retail sales projected for 2024 [1]

Group 1 - UBS downgraded the rating of Giant Bio (02367) from "Buy" to "Neutral" due to increased uncertainty in short-term revenue and profit outlook [1] - The profit forecast for 2025 to 2027 was cut by 25% to 41%, with revenue projections reduced by 20% to 36% during the same period [1] - The target price was significantly lowered from HKD 79.5 to HKD 39.5 [1] Group 2 - The report indicates intensified market competition, with the emergence of other skincare brands or products that offer more attractive pricing while also focusing on collagen restructuring [1] - Despite rapid product innovation, there is uncertainty regarding the success of new products in the coming year [1] - Maintaining high profitability is expected to be challenging in the context of increased competition and weakened marketing efficiency, with a projected erosion of 2 to 3 percentage points in net profit margin due to reduced marketing efficiency and operational deleveraging [1]

Industry Overview - Collagen masks are mainstream skincare products focused on anti-aging and repair, utilizing collagen as the core ingredient along with auxiliary components to achieve hydration and skin barrier repair [1][2] - The Chinese mask industry is expected to reach a market size of 72.986 billion yuan in 2024, entering a period of adjustment and transformation, facing growth slowdown and intensified competition [1][6] - The collagen market is experiencing explosive growth, with a compound annual growth rate (CAGR) of 41.9% from 2020 to 2023, and retail scale expected to exceed 269.5 billion yuan by 2030 [1][7] Market Dynamics - The market structure in China shows that sheet masks remain dominant, while cream masks are rapidly growing, focusing on hydration and repair needs [1][7] - The competitive landscape features local leaders dominating, niche players breaking through, and international brands penetrating the market, with a clear price gradient and significant differentiation between high, medium, and low-end markets [1][8] Industry Chain - The upstream of the collagen mask industry primarily uses animal-derived collagen, while recombinant collagen is rapidly developing due to its high purity and compatibility with mask formulations [6][10] - The manufacturing process involves various technologies to convert raw materials into different forms and functions of mask products, with sales channels dominated by online e-commerce and deepening offline professional channels [6][10] Current Development - The Chinese mask industry is transitioning into a phase of deep integration after rapid growth, with three emerging drivers leading market changes: consumption upgrades, male skincare market expansion, and personalized demand fostering innovative scenarios [6][7] - The market size is projected to steadily grow to 76.79 billion yuan by 2025 and potentially exceed 146.42 billion yuan by 2030, indicating robust long-term growth prospects [6][7] Key Players - Major companies in the collagen mask industry include Juzi Biotechnology, Huaxi Biotechnology, and Marubi Biotechnology, leveraging differentiated technologies and channel advantages to lead the market [2][10] - The industry is characterized by a multi-faceted competitive ecosystem, with local leaders, niche players, and international brands all contributing to the market dynamics [10] Future Trends - The industry is expected to advance towards high-end technology, refined products, and standardized ecosystems, with a focus on cross-disciplinary technology integration and precise formulations [10][12] - Regulatory tightening is anticipated to accelerate the elimination of smaller brands, increasing market concentration, while leading companies will strengthen their market positions through R&D innovation and global expansion [10][14]

Core Viewpoint - The stock price of Hyaluronic Acid leader, Huaxi Biological (688363.SH), has fallen below its issue price, raising concerns among investors about the company's measures to reverse this trend [1][2]. Group 1: Stock Performance and Market Reaction - On December 4, Huaxi Biological's stock price dropped to 45.25 yuan per share (post-adjusted to 47.62 yuan), below the issue price of 47.79 yuan, indicating a significant market reaction [1]. - The company has seen its market capitalization shrink from over 140 billion yuan at its peak to approximately 22 billion yuan, with a cumulative stock price decline of 10.53% this year [3]. - The stock has reached a historical low of 42.42 yuan per share during the year, reflecting ongoing investor concerns [3]. Group 2: Financial Performance - For the first three quarters of 2025, Huaxi Biological reported revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit of 252 million yuan, down 30.29% [2]. - Despite a 55.63% increase in net profit in the third quarter compared to the previous year, the revenue of 900 million yuan still represented a 15.16% decline, indicating a situation of "profit increase without revenue increase" [2]. Group 3: Shareholder Actions and Market Sentiment - The second-largest shareholder, Guoshou Chengda, plans to reduce its holdings by up to 9.6336 million shares, approximately 2% of the total share capital, further intensifying market concerns [3]. - Institutional investors, including several fund companies, have also been reducing their stakes in Huaxi Biological, indicating a broader withdrawal of capital from the company [3]. Group 4: Industry Challenges and Strategic Responses - Huaxi Biological has been removed from two major indices, including the STAR 50 Index and the FTSE China A400 Index, which may impact its visibility and investor sentiment [4]. - The company faces increased competition, particularly from collagen-based products, which are projected to surpass hyaluronic acid in market share by 2026, with a compound annual growth rate of 52.6% [4]. - In response to these challenges, Huaxi Biological is undergoing organizational restructuring and investing in new biotechnologies, such as PDRN and ergothioneine, to enhance its product offerings and performance [4].

Core Viewpoint - CICC has downgraded the net profit forecast for Giant Bio (02367) for 2025-2026 by 25% and 33% to 1.91 billion and 2.14 billion yuan respectively, citing short-term pressure on cosmetics sales. The current stock price corresponds to a P/E ratio of 20x for 2025 and 18x for 2026. The target price has been reduced by 20% to 56 HKD, which implies a potential upside of 41% based on the adjusted earnings forecast [1]. Company Current Situation - On December 2, the company announced a plan to repurchase up to 104 million shares, accounting for 10% of the issued shares, and is communicating its strategic plans for 2026 regarding product matrix expansion, brand operation, and channel development. This repurchase reflects management's confidence, and the company’s R&D capabilities, brand recognition, and team cohesion remain strong, suggesting potential operational improvements through optimized product structure and timely operational adjustments [2][3]. Product and Channel Expansion Plans - The company has a rich reserve of new products for 2026, with plans to launch four key new products in the collagen repair series and expand channel coverage for existing brands. The company aims to strengthen its online presence and expand offline channels, including clinics and self-operated stores, with successful initial steps in Southeast Asia. The contribution from second-tier products is expected to increase, driving healthy growth in the cosmetics business [4]. Medical Aesthetics Growth - The medical aesthetics team is expanding, with strong experience in developing star products and commercial preparations progressing smoothly. The company’s R&D strength, brand recognition, and team cohesion are expected to support long-term growth, especially as the cosmetics market recovers and the medical aesthetics segment contributes additional growth [5].

Core Viewpoint - CICC has downgraded the profit forecast for Giant Bio (02367) for 2025-2026 by 25% and 33% to 1.91 billion and 2.14 billion yuan respectively, reflecting short-term pressure on cosmetics sales. The current stock price corresponds to a P/E of 20x for 2025 and 18x for 2026. The target price has been reduced by 20% to 56 HKD, indicating a potential upside of 41% based on the adjusted profit forecast [1]. Company Current Situation - On December 2, the company announced a plan to repurchase up to 104 million shares, accounting for 10% of the issued shares, and communicated its strategic plans for 2026 regarding product matrix expansion, brand operation, and channel development. This repurchase reflects management's confidence, and the company is expected to improve operations through optimized product structure and timely operational adjustments [2][3]. Share Repurchase Plan - The company plans to use its own funds to repurchase up to 104 million shares, which may be canceled or held as treasury stock. This repurchase plan is seen as a demonstration of management's long-term confidence in the company's growth and is expected to enhance earnings per share and shareholder returns [3]. Product Matrix and Channel Expansion Planning - For 2026, the company has a rich reserve of new products, including four key new products from the core collagen stick marketing and pricing strategy. Additionally, the company plans to upgrade its product lines and expand channel coverage, including online influencer marketing and offline distribution channels. The second-tier products are expected to contribute to healthy growth in the cosmetics business [4]. Medical Aesthetics Second Curve Progress - The company's medical aesthetics team is expanding, with successful commercialization preparations based on previous experience in developing star products. The company maintains strong R&D capabilities, brand recognition, and team cohesion, suggesting a broad growth space as the cosmetics market recovers and the medical aesthetics segment contributes additional revenue [5].

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside of 15% to 35% from the current price [5][10]. Core Insights - The company plans to repurchase up to approximately 104 million shares, which is about 9.7% of its total shares, signaling management's confidence in the company's future and belief that the stock is undervalued [6][7]. - The company has received its first Class III medical device certification for its recombinant type I α1 collagen product, marking its entry into the injectable aesthetic medicine market, which is expected to drive future growth [7]. - Despite recent stock price adjustments due to market conditions and lower-than-expected sales during the Double Eleven shopping festival, the report suggests that the stock has sufficiently adjusted and is poised for recovery [7]. Financial Projections - The company is projected to achieve net profits of RMB 2.43 billion, RMB 2.98 billion, and RMB 3.64 billion for the years 2025, 2026, and 2027, respectively, reflecting year-over-year growth rates of 17.8%, 22.5%, and 22.2% [9]. - Earnings per share (EPS) are expected to be RMB 2.27, RMB 2.78, and RMB 3.40 for the same years, with corresponding year-over-year growth rates of 8.1%, 22.5%, and 22.2% [9]. - The price-to-earnings (P/E) ratios are projected to decrease from 15x in 2025 to 10x in 2027, indicating a potential increase in value as the company grows [9]. Shareholder Information - The major shareholder is Fan Daidi, holding 55.13% of the shares, which indicates a strong control over the company [1]. - The company's market capitalization is approximately HKD 41.08 billion, with a current share price of HKD 36.58 [1]. Market Performance - The stock has experienced a significant decline, with a 24.4% drop over the past month and a 32.07% drop over the past three months [1]. - The stock price has fluctuated between a high of HKD 82.99 and a low of HKD 35.72 over the past year [1]. Product Portfolio - The company's product mix is heavily weighted towards functional skincare products, which account for 78.6% of total sales, while medical dressings contribute 23.3% and health products account for 0.3% [2].

Group 1 - The core viewpoint of the article highlights that the stock price of Giant Bio (02367) has dropped over 3%, reaching a new low of 35.54 HKD, which is a significant decline from its peak in May [1] - The stock price has halved since its high point in May, indicating a severe downturn influenced by public opinion regarding collagen ingredients [1] - As of the report, the stock is down 3.46%, trading at 35.68 HKD with a transaction volume of 199 million HKD [1] Group 2 - According to Qingyan Intelligence, domestic brands secured 5 spots in the top 10 of the Douyin beauty list for this year's Double Eleven, while Giant Bio's brand, Kefu Mei, has fallen out of the top 10 [1] - On the Tmall beauty list for Double Eleven, Kefu Mei ranked 18th, a drop of 5 places compared to last year [1] - Reports indicate that Kefu Mei has consistently fallen out of the top 20 on the Douyin beauty list since June of this year [1] Group 3 - Jianghai Securities suggests that the increasing number of players in the collagen industry warrants attention on Giant Bio's future marketing strategies and sales performance for their products [1]